

Clinical trials of Esapent

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

| Trial | Treatments | Patients | Trials design and methods |
|--|--|--|--|
| Esapent vs placebo | | | |
| Maresta , 2002 n=169/170 follow-up: 7 months | Esapent capsules, 6/d for 2 mo, then 3/d (5.1g/d EPA + DHA initially, later 2.6g/d) versus placebo (identical olive oil capsules, 6/d for 2 mo, then 3/d) | undergoing planned PTCAB | Parallel groups double-blind Italy |
| Sirtori , 1998 n=470/465 follow-up: 6 months | Esapent fish oil capsules 3/d for first 2 mo, 2/d after that (2.6g/dEPA + DHA initially, then 1.8g/d) versus placebo (olive oil capsules 3/d for first 2 mo, 2/d after that) | people with raised triglycerides plus glucose intolerance, non-insulindependent diabetes or hypertension | Parallel groups double blind Italy |

More details and results :

- omega-3 fatty acids for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q121>
- omega-3 fatty acids for cardiovascular prevention in patients at high risk at <http://www.trialresultscenter.org/go-Q123>

References

Maresta, 2002:

Skali H, Solomon SD, Pfeffer MA Are we asking too much of our trials? Am Heart J 2002 Jan;143:1-3 [[11773904](#)]

Sirtori, 1998:

Sirtori CR, Crepaldi G, Manzato E, Mancini M, Rivellesse A, Paoletti R, Pazzucconi F, Pamparana F, Stragliotto E One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis 1998;137:419-27 [[9622285](#)]